Back to top
more

Actinium Pharmaceuticals (ATNM)

(Delayed Data from AMEX)

$1.60 USD

1.60
73,543

-0.02 (-1.23%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $1.60 0.00 (0.00%) 7:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (83 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View

by Zacks Equity Research

CORT beats on both earnings and sales in the third quarter of 2024. The company increases the revenue guidance for 2024. Stock falls in after-hours trading.

Zacks Equity Research

Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates

by Zacks Equity Research

AMRN's third-quarter 2024 earnings meet estimates while revenues miss the same. Vascepa's sales in the United States decline year over year. Stock falls.

Zacks Equity Research

All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy

by Zacks Equity Research

Actinium (ATNM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Actinium Pharmaceuticals (ATNM) and Encompass Health (EHC) have performed compared to their sector so far this year.

Zacks Equity Research

Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Affimed N.V. (AFMD) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

Zacks Equity Research

Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of -9.89% and 4.01%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Finch Therapeutics Group, Inc. (FNCH) delivered earnings and revenue surprises of -12.50% and 90.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Actinium (ATNM) Stock Jumps 8.6%: Will It Continue to Soar?

by Zacks Equity Research

Actinium (ATNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

CV Sciences, Inc. (CVSI) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 0% and 15.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -13.98% and 20.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Organogenesis (ORGO) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Organogenesis (ORGO) delivered earnings and revenue surprises of 12.50% and 0.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aurinia (AUPH) delivered earnings and revenue surprises of -13.64% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Has Alkermes (ALKS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Alkermes (ALKS) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

Zacks Equity Research

Actinium (ATNM) Up on Commercialization Deal With Immedica

by Zacks Equity Research

Actinium (ATNM) out-licenses exclusive rights to Iomab-B, an antibody radiation conjugate for facilitating bone-marrow transplant, to Immedica in Europe, the Middle East and North African countries.

Zacks Equity Research

Is Apria (APR) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Apria (APR) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

Zacks Equity Research

Surging Earnings Estimates Signal Good News for Actinium (ATNM)

by Zacks Equity Research

Actinium (ATNM) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Zacks Equity Research

Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Actinium Pharmaceuticals (ATNM) closed the most recent trading day at $11.22, moving +0.9% from the previous trading session.

Zacks Equity Research

Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Actinium Pharmaceuticals (ATNM) closed the most recent trading day at $11.40, moving -1.04% from the previous trading session.

Zacks Equity Research

Actinium Pharmaceuticals (ATNM) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $11.11, marking a +0.63% move from the previous day.

Zacks Equity Research

Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $10.35, marking a +0.78% move from the previous day.

Zacks Equity Research

Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $11.16, marking a -1.06% move from the previous day.

Zacks Equity Research

Actinium Pharmaceuticals (ATNM) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Actinium Pharmaceuticals (ATNM) closed at $12.01 in the latest trading session, marking a +0.5% move from the prior day.

Zacks Equity Research

Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ATNM) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Actinium Pharmaceuticals (ATNM) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $11.82, marking a +0.34% move from the previous day.

Zacks Equity Research

Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $10.15, marking a +1.2% move from the previous day.